23,99 €
inkl. MwSt.
Versandfertig in 6-10 Tagen
12 °P sammeln
Andere Kunden interessierten sich auch für
![A Snapshot On The Major Pharmaceutical Companies In India]( "A Snapshot On The Major Pharmaceutical Companies In India")
A Snapshot On The Major Pharmaceutical Companies In India23,99 €![Endocrine Disruptors - A Major Medical Challenge]( "Endocrine Disruptors - A Major Medical Challenge")
Endocrine Disruptors - A Major Medical Challenge32,99 €![The Major Approaches for Boosting Aqueous Solubility, Dissolution Rate, and Oral Bioavailability]( "The Major Approaches for Boosting Aqueous Solubility, Dissolution Rate, and Oral Bioavailability")
The Major Approaches for Boosting Aqueous Solubility, Dissolution Rate, and Oral Bioavailability51,99 €![Hypertension: A major factor for epilepsy]( "Hypertension: A major factor for epilepsy")
Hypertension: A major factor for epilepsy32,99 €![STUDIES ON SOME SIDE EFFECTS OF CEPHALOSPORINS]( "STUDIES ON SOME SIDE EFFECTS OF CEPHALOSPORINS")
STUDIES ON SOME SIDE EFFECTS OF CEPHALOSPORINS32,99 €![Reducing GI side effects of NSAIDs by Mutual prodrug approach]( "Reducing GI side effects of NSAIDs by Mutual prodrug approach")
Reducing GI side effects of NSAIDs by Mutual prodrug approach32,99 €![Role of Hepcidin Hormone in Patients of ß-Thalassemia Major]( "Role of Hepcidin Hormone in Patients of ß-Thalassemia Major")
Role of Hepcidin Hormone in Patients of ß-Thalassemia Major34,99 €
Cisplatin (CDDP) is a major antineoplastic drug for the treatment of solid tumors such as metastatic bladder, testicular, and ovarian carcinomas. The drug can cause much toxicity, but the chief dose-limiting one is nephrotoxicity. Several, often interrelated mechanisms of actions have been hypothesized to induce the nephrotoxicity. These include apoptosis and inflammatory mechanism, production of tumor necrosis factor (TNF)- by renal parenchymal cells, and generation of reactive oxygen species (ROS) that include superoxide dismutase, hydrogen radical, hydrogen peroxide, singlet oxygen, and nitric oxide. These techniques have proved to be only partially successful as acute renal failure occurs even at such low doses and especially after its repeated administration. The nephrotoxicity of cisplatin has been recognized since its introduction over 25 years ago. Early clinical use of cisplatin saw dose-related cisplatin-induced acute renal failure in 14 to 100% of patients, with the incidence varying with the cumulative dose. Clinical data have shown that approximately one third of patients experience kidney injury in days after cisplatin treatment, with reduced glomerular filtration.